Sulfated Polysaccharides
1. Identity: Chemical Nomenclature, Natural Sources, and Common Forms
1.1 Chemical Definition
Sulfated polysaccharides (SPs) are polysaccharides containing sulfate groups on sugar units. More precisely, polysaccharides are long-chain carbohydrates composed of repeating monosaccharide units; when these polysaccharides undergo sulfation, sulfate groups (–SO₃) are added to the sugar units. This modification significantly alters their physical and chemical properties, enhancing their solubility and bioactivity. The sulfation of polysaccharides can occur at various positions on the sugar units, leading to a wide variety of structures with different biological functions.
Characterized by their unique sulfate ester groups and structural diversity, SPs exhibit a broad spectrum of bioactivities, including immunomodulation, apoptosis induction, metastasis suppression, and angiogenesis inhibition.
1.2 Natural Sources and Classification
On the basis of their sources, SPs are usually categorized as animal-derived bioactive (dermatan sulfates, chondroitin sulfate, and heparin), plant-derived bioactive (sulfated galactan from the marine plant Ruppia maritima), microorganisms-derived bioactive (sulfated monophosphorylated mannose oligosaccharide, mushrooms, exopolysaccharides and capsular polysaccharides), and seaweed. Marine bioactive are the richest resource of SPs; among all of these, marine algae have the greatest number of SPs.
Brown, green, and red algae are the three types of seaweed whose sulfated polysaccharide contents range from 4 to 76%, whereas green seaweed alone yields nearly 65% dry weight.
Natural polysaccharides derived from plants, fungi and animals are well known as ideal functional products with multiple biological activities and few side effects. Natural occurring sulfated polysaccharides and those from synthetic origin are increasingly causing more attention worldwide, as they have been proved to possess broad-spectrum antiviral activities.
1.3 Major Individual Sulfated Polysaccharides
The most scientifically studied sulfated polysaccharides include the following:
- Fucoidan: A long-chain sulfated polysaccharide found in various species of brown algae, such as seaweed, and in marine invertebrates. Commercially available fucoidan is commonly extracted from the seaweed species Fucus vesiculosus (wracks), Cladosiphon okamuranus, Laminaria japonica (kombu, sugar kelp) and Undaria pinnatifida (wakame). The main sugar found in the polymer backbone is fucose, giving the name fucoidan. Other sugars are often present alongside fucose, including galactose, xylose, arabinose and rhamnose.
- Carrageenans: Carrageenans are a family of linear SPs extracted from red seaweeds, including Gracilaria, Gigartina, Gelidium, Lomentaria, Corallina, Champia, Solieria, Gyrodinium, Nemalion, Sphaerococcus, Boergeseniella, Sebdenia, Scinaia, and others. This group has a backbone of alternating 3-linked β-D-galactose and 4-linked α-D-galactose residues. Three categories of carrageenans — kappa (κ), iota (ι), and lambda (λ) — have been identified based on their sulfation degree, solubility, and gelling properties. There are three main classes of carrageenan, which differ in degree of sulfation: kappa-carrageenan has one sulfate group per disaccharide, iota-carrageenan has two, and lambda-carrageenan has three.
- Chondroitin Sulfate: Chondroitin sulfate (CS) is a natural macromolecule polysaccharide that is extensively distributed in a wide variety of organisms. CS production derives from diverse sources, including extraction from various animals or fish, bio-synthesis, and fermentation, and its purity and homogeneity can vary greatly. The structural diversity of CS with respect to sulfation and saccharide content endows this molecule with distinct complexity, allowing for functional modification.
- Heparin: Heparin has been used clinically as an anticoagulant for over 60 years. Typically isolated from porcine intestine, heparin is a mixture of dimeric glycosidic sequences generating complex polysaccharide glycosaminoglycan chains.
- Ulvan: The cell walls of marine algae are rich in sulfated polysaccharides, including carrageenan in red algae, ulvan in green algae, and fucoidan in brown algae.
1.4 Structural Chemistry and Structure–Activity Relationships
The major sulfated polysaccharides synthesized by seaweeds include the galactans (e.g., agarans and carrageenans), ulvans, and fucans. The anticoagulant activity of sulfated polysaccharides is linked to the substitution site of sulfate groups, degree of substitution, molecular weight, main side chain structure, and glycosidic bond configuration.
The biological activities of fucoidans are closely linked to their molecular weight and sulfate content. Several studies have reported that low-molecular-weight fucoidan (LMWF) is more biologically active than high-molecular-weight fucoidans (HMWF). However, LMWF obtained from acidic hydrolysis leads to reduced bioactivities due to the removal of sulfate groups.
1.5 Common Forms and Preparations
Fucoidan is sold as a dietary supplement, food additive, and as an ingredient in animal feed or cosmetics. Carrageenans are widely used in the food industry for their gelling, thickening, and stabilizing properties. A primary application is in dairy and meat products, due to the strong binding of carrageenans to food proteins. Sulfated polysaccharides have been increasingly studied over the years in the pharmaceutical field, given their potential usefulness in applications such as the design of drug delivery systems.
There are many methods for sulfated modification, such as chlorosulfonic acid-pyridine method, concentrated sulfuric acid method, and sulfur trioxide-pyridine method, which could improve anti-coagulant, anti-oxidative, immunoregulation, anti-tumor, and anti-virus activities of polysaccharides.
2. Traditional and Historical Use
2.1 East Asian Traditions
Historically, seaweeds have a traditional usage, especially in Asian countries, as herbal medicine for the treatment of tumors, neurodegenerative diseases, urinary problems, and gastrointestinal issues. Brown seaweeds containing fucoidan are extensively used as part of the regular diet in East Asia, particularly in Japan, China, and Korea.
Despite their use in traditional Chinese and Japanese folk medicines, only in the current years were they commercialized as nutritional supplements. Fucoidans, discovered in 1913, are fucose-rich sulfated polysaccharides extracted mainly from brown seaweed. Although used in traditional Chinese medicine, fucoidan has not been approved as a human drug in any country, and no advanced clinical trials had been reported as of 2019.
2.2 Historical Use of Heparin and Animal-Derived SPs
Heparin has been used clinically as an anticoagulant for over 60 years. It represents the oldest and most established clinical application of a naturally derived sulfated polysaccharide. Propylene glycol alginate sodium sulfate (PSS), a sulfated polysaccharide derivative, has been used as a heparinoid drug to prevent and treat hyperlipidemia and ischemic cardio-cerebrovascular diseases in China for 30 years.
2.3 Commercial and Research History of Fucoidan
Research in the early 20th century focused on extracting crude extracts of fucoidan. Methods of extraction and isolation from brown seaweeds were determined on laboratory scale in 1952. Laboratory research expanded once fucoidan became commercially available in the 1970s, with studies limited to in vitro and rodent studies.
3. Key Constituents, Active Compounds, and Mechanisms of Action
3.1 Structural Determinants of Activity
SPs abundantly available in marine sources are characterized by higher molecular weight, molecular geometry, backbone and linkage, enriched amount of sulfate content, and sulfate groups in the polysaccharide chain. These are main precursors directly involved in interaction with different proteins in the matrix and cells, resulting in regulation of several pathways and biomarkers.
One of the primary mechanisms by which polysaccharide sulfates exert their effects is through their interaction with proteins, particularly those involved in cellular signaling. These interactions are largely mediated by electrostatic forces between the negatively charged sulfate groups and positively charged regions on the proteins. For instance, polysaccharide sulfates can bind to growth factors, cytokines, and enzymes, modulating their activity and stability. This can result in the inhibition or enhancement of various biological pathways, depending on the specific context.
3.2 Anticoagulant Mechanism
Fucoidans exhibit anticoagulant and antithrombotic activity mediated by heparin cofactor II and other blood-clotting factors. These effects are also associated with the ability of sulfated polysaccharides to potentiate the interaction of thrombin with antithrombin (ATIII) or heparin cofactor II (HCII). Other pathways include direct inhibition of thrombin and factor Xa. Fucoidans with a higher molecular weight tend to show a more pronounced anticoagulant effect, while a certain sulfation rate is essential for anticoagulant activity.
3.3 Immunomodulatory Mechanism
The mechanisms by which sulfated polysaccharides exert their immunological activity is mainly due to the regulation of macrophage function, natural killer cells, and T/B lymphocytes, together with the stimulation of the immune responses of lymphocytes and the activation of the complement system. The immunological activity of sulfated polysaccharides depends not only on the source of the polysaccharide but also on structural characteristics, such as molecular weight and degree of substitution. Studies on the mechanisms of immune function have shown that the action of sulfated polysaccharides is a complex process that may be regulated by one or more pathways.
3.4 Anticancer Pathway Mechanisms
Mechanisms of action in cancer contexts involve targeting critical pathways such as NF-κB, VEGF, and PI3K/Akt, disrupting cancer cell proliferation, invasion, and tumor microenvironment dynamics. SPs also enhance immune system responses, reduce chemotherapy-induced side effects, and exhibit antioxidant properties, making them versatile candidates in cancer treatment.
3.5 Antiviral Mechanism
Sulfated polysaccharides are found on the surfaces of both the susceptible host cells and the majority of human viruses, and thus can play an important role during viral infection. Extracellular polysaccharides, particularly sulfated polysaccharides, are among the most widespread and potent extracellular and secreted molecules blocking and deactivating bacteria, fungi, and viruses. These molecules interact with biochemical signaling in immune cell responses, by actions in oxidative reactions, cytokine signaling, receptor binding, and through antiviral and antibacterial toxicity.
3.6 Anti-Inflammatory Mechanism
Sulfated polysaccharides, such as carrageenan from seaweed, exert immunomodulatory effects closely linked to their sulfate groups. They interact with C-type lectin receptors (e.g., DC-SIGN) to regulate dendritic cell and T cell functions. Additionally, sulfated polysaccharides can inhibit complement activation, reducing inflammatory responses.
The ability of polysaccharides to scavenge free radicals has been seen to aid in reducing inflammation. Pro-inflammatory substances like prostaglandins, leukotrienes, and inflammatory cytokines cannot be produced as easily when polysaccharides from seaweed are present.
3.7 Gut Microbiota Interaction
Few of the non-starch polysaccharides are digested by the mammalian intestine and reach the colon intact to serve as an energy source for the intestinal flora, stimulating their growth and producing healthy metabolites. Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are metabolic products produced by gut microbiota through the fermentation of dietary fibers. Algae-derived polysaccharides resist human digestive enzymes but can be fermented by gut bacteria.
4. Scientific Evidence by Area of Use
4.1 Anticoagulant and Antithrombotic Activity
In vitro and animal evidence: Fucoidans exhibit anticoagulant activity that is largely dependent on the seaweed from which they are extracted. For most fucoidans, increases in both activated partial thromboplastin time (aPTT) and thromboplastin time (TT) were observed, on a scale either comparable to or higher than heparin. In general, anticoagulation from fucoidan appeared to depend on a higher sulfate content, increased molecular weight, and position of sulfate groups on the backbone.
Human/clinical evidence: A single-blind clinical study evaluated the anticoagulant activity of fucoidan from Undaria pinnatifida, with 10 subjects receiving 3 g of fucoidan capsules for 12 days (the 10 subjects in the control group received guar gum capsules). Despite the fact that preliminary in vitro studies had revealed a pronounced anticoagulant activity, no effect on hemostasis in vivo was apparent, probably due to low intestinal absorption.
Evidence strength: The anticoagulant effects of marine sulfated polysaccharides are well-demonstrated in vitro and in animal models. However, human clinical evidence is very limited and has not shown significant anticoagulant effects from oral supplementation, possibly due to poor bioavailability. Notably, sulfated polysaccharides exhibit favorable anticoagulant efficacy with reduced side effects relative to heparin in laboratory models, but translation to clinical use has not been established.
4.2 Anticancer and Antitumor Activity
In vitro and animal evidence: Due to its range of biological effects, including antitumor, antioxidative, antiviral, anti-inflammatory, anticoagulation, and immunoregulatory activities, fucoidan has been considered to have great clinical potential. Many animal experiments and in vitro experiments have been conducted exploring the antitumor effect of fucoidan. Tumor types studied have included colorectal cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, liver cancer, melanoma, multiple myeloma, and sarcoma.
Fucoidans have a wide range of favorable biological activities, including antitumor, immunomodulatory, antiviral, antithrombotic, anticoagulant, antioxidant, and lipid-lowering activities. In the early 1980s, fucoidans were first recognized for their role in supporting the immune response, and later, in the 1990s, their effects on immune potentiation began to emerge. In recent years, the understanding of the immunomodulatory effects of fucoidan has expanded significantly.
Human/clinical evidence: The activity of various fucoidans and their derivatives has been demonstrated in vitro on tumor cells of different histogenesis and in experiments on mice with grafted tumors. However, these experimental models showed low levels of antitumor activity, and clinical trials did not prove that this class of compounds could serve as antitumor drugs.
Nevertheless, the anti-inflammatory, antiangiogenic, immunostimulating, and anticoagulant properties of fucoidans, as well as their ability to stimulate hematopoiesis during cytostatic-based antitumor therapy, suggest that effective fucoidan-based drugs could be designed for the supportive care and symptomatic therapy of cancer patients.
Evidence strength: Preclinical evidence for antitumor activity is substantial, spanning numerous in vitro and rodent models. Rigorous human clinical trial evidence is currently lacking. The current scientific consensus is that fucoidan and related SPs show promise as adjunctive agents in oncology supportive care rather than as standalone antitumor drugs.
4.3 Metabolic Disorders: Cardiovascular, Lipid, and Glycemic Effects
In vitro and animal evidence: Groups of SP biomacromolecules such as fucoidan, rhamnan sulfate, fucosylated chondroitin sulfate, laminarin sulfate, agar, heteroglycans, fucan sulfate, alginate, ulvan A, ulvan B, xylan, galactan, and carrageenan have been extensively studied for their beneficial role in the management of metabolic disorders. Antioxidant, antidiabetic, antihyperlipidemic, anti-inflammatory, cardioprotective, hepatoprotective, chemo-preventive, anti-obesity, and anti-MASLD benefits of SPs have been recognized.
The antihypertensive, antidiabetic, antiobesity, and hypolipidemic effects of fucoidan have been reported in preclinical research and clinical trials. In rodent models, fucoidan treatment (100 or 200 mg/kg for 5 weeks) in diabetic mice significantly improved glucose tolerance, lipid metabolism, and liver function, while reducing hepatic steatosis and serum ALT/AST levels. Fuc-S enhanced hepatic antioxidant defenses, increasing SOD, CAT, and GSH-Px activity while decreasing MDA levels.
Human/clinical evidence: Two clinical studies with an Ulva sp.-derived sulfated polysaccharide ("xylorhamnoglucuronan," SXRG84) examined metabolic markers, inflammation, and gut flora composition. The first study was a double-blind, randomized placebo-controlled trial with placebo, and either 2 g/day or 4 g/day of SXRG84 daily for six weeks in 64 overweight or obese participants (median age 55 years, median BMI 29 kg/m²).
In Study 1, the 2 g/day dose exhibited a significant reduction in non-HDL cholesterol (−10% or −0.37 mmol/L, p = 0.02) and in the atherogenic index (−50%, p = 0.05), and two-hour insulin (−12% or −4.83 mU/L) showed trends for reduction in overweight participants. CRP (C-reactive protein) was significantly reduced (−27% or −0.78 mg/L, p = 0.03) with the 4 g/day dose in overweight participants. Significant gut flora shifts included increases in Bifidobacteria, Akkermansia, Pseudobutyrivibrio, and Clostridium and a decrease in Bilophila.
In Study 2, no significant differences in lipid measures were observed, but inflammatory cytokines were improved. At twelve weeks after the SXRG84 treatment, plasma cytokine concentrations were significantly lower than at six weeks post placebo for IFN-γ (3.4 vs. 7.3 pg/mL), IL-1β (16.2 vs. 23.2 pg/mL), TNF-α (9.3 vs. 12.6 pg/mL), and IL-10 (1.6 vs. 2.1 pg/mL) (p < 0.05).
Evidence strength: Promising but early-stage. Preclinical data in rodents (diabetes, dyslipidemia, obesity) is extensive. A small number of randomized clinical trials in humans have shown statistically significant improvements in select lipid and inflammatory markers at specific doses, but sample sizes are modest, and findings were not entirely consistent across the two SXRG84 studies described above. Larger, multi-center trials are needed.
4.4 Antiviral Activity
Four marine sulfated polysaccharides were screened for their inhibitory activity against SARS-CoV-2, including sea cucumber sulfated polysaccharide (SCSP), fucoidan from brown algae, iota-carrageenan from red algae, and chondroitin sulfate C from shark (CS). A test using a pseudotype virus with S glycoprotein confirmed that SCSP could bind to the S glycoprotein to prevent SARS-CoV-2 host cell entry. These four polysaccharides were found to be promising inhibitors of SARS-CoV-2 infection.
In particular, the antiviral actions of the sulfated polysaccharides derived from marine algae, including carrageenans, alginates, and fucans, relate to their structure features and the structure–activity relationships. New research reveals that a range of polysaccharides effectively inhibits COV-2 infection of mammalian cells in culture.
Evidence strength: The bulk of current antiviral evidence for SPs is from in vitro cell culture studies. It is important to acknowledge the limitations of the available research, including the variability in seaweed sources and extraction methods, and the reliance on in vitro studies. Clinical trials in humans evaluating antiviral effects of SPs are lacking.
4.5 Immunomodulatory Activity
The mechanisms by which sulfated polysaccharides exert their immunological activity is mainly due to the regulation of macrophage function, natural killer cells, and T/B lymphocytes. A large number of studies have characterized and evaluated the biological relevance of sulfated polysaccharides, which shows great potential in terms of immunological activity.
The ability of fucoidan to activate CTL-mediated cytotoxicity against cancer cells, its strong antitumor property, and robust safety profile make fucoidans desirable for effective cancer immunotherapy. However, this conclusion is primarily drawn from preclinical evidence, and robust clinical trials validating immunomodulatory endpoints in humans remain limited.
4.6 Joint Health: Osteoarthritis (Chondroitin Sulfate)
Over the years, chondroitin sulfate (CS) has been used as a slow-acting drug for the treatment of osteoarthritis, for the reduction of pain and improvement of function, and for its disease-modifying properties by limiting cartilage volume loss and joint space narrowing progression. However, there have been inconsistencies in published trials regarding clinical efficacy, with reports of a lack of significant effects compared to placebo. The therapeutic effects of chondroitin sulfate may depend on many variables, such as the source of origin, purity, and contamination with by-products.
A review concluded that pharmacologic-grade CS supplements may have clinically significant benefits when properly standardized; however, high-quality evidence from properly designed clinical trials is still needed to draw definitive conclusions about clinical efficacy in osteoarthritis.
Evidence strength: Mixed. CS is among the most extensively human-tested SPs in the context of osteoarthritis. Evidence is inconsistent across trials; some meta-analyses show modest benefits in pain and function, while others show no difference from placebo. Quality, source, and purity of CS preparations significantly affect outcomes.
4.7 Gut Microbiota and Intestinal Health
Natural polysaccharides have attracted considerable attention as potential therapeutic agents for inflammatory bowel disease (IBD) owing to their high efficiency, low toxicity, and wide range of biological activities. Intestinal microbiota and their fermentative products, mainly short-chain fatty acids, are thought to mediate the effect of natural polysaccharides in IBDs. They are also characterized by low toxicity, immunity enhancement, and prebiotic properties, in addition to facilitating IBD remission.
A 16S rRNA gene sequencing analysis showed that native Chinese yam polysaccharide regulated gut microbiota by decreasing Desulfovibrio and Sutterella and increasing Prevotella. The sulfated form changed the gut microbiota by decreasing Desulfovibrio and increasing Coprococcus, which reversed the microbiota dysbiosis caused by LPS.
Evidence strength: Primarily animal model and in vitro evidence; the human data described in the SXRG84 clinical trials above (section 4.3) represents some of the best available clinical evidence for prebiotic/microbiome effects, with statistically significant gut flora shifts noted. Clinical trial data specifically on IBD in humans using SPs remains limited.
5. Body Systems and Health Areas
Based on the reviewed literature, SPs are associated with the following body systems and health areas:
- Cardiovascular system: Anticoagulant and antithrombotic activities, lipid-lowering effects, antiatherosclerotic activity. Laminarin appeared to have a greater effect on atherosclerosis risk factors in its sulfated form, and fucoidan, laminarin sulfate, and carrageenan were shown to directly hinder atherosclerotic lesion development in animal models.
- Immune system: Modulation of macrophages, natural killer cells, T/B lymphocytes, dendritic cells, and complement system.
- Oncology (supportive): Immunostimulation, angiogenesis inhibition, hematopoiesis support during chemotherapy.
- Metabolic health: Scientific and clinical studies on SPs involve the management of obesity, cardiovascular disease, diabetes, metabolic syndrome associated steatotic liver disease, and dyslipidaemia.
- Musculoskeletal system: Chondroitin sulfate for osteoarthritis, cartilage preservation, and joint space narrowing.
- Virology/Infectious disease: Broad-spectrum antiviral properties, particularly against enveloped viruses; activity against SARS-CoV-2 in vitro.
- Gastrointestinal system: Prebiotic activity, gut microbiota modulation, short-chain fatty acid production, IBD-related anti-inflammatory effects.
- Antioxidant defense: Numerous polysaccharides derived from seaweed have a high concentration of antioxidants, facilitating the mitigation of oxidative stress inside the human body. The presence of oxidative stress has been shown to be linked to the occurrence of inflammation.
6. Dosage Forms and Reported Dosages
Fucoidan is sold as a dietary supplement, food additive, and as an ingredient in animal feed or cosmetics. Carefully controlled sources of seaweed together with modern extraction and characterization methods to create reproducibly defined products together with new regulatory avenues mean that fucoidan fractions can be produced to standards suitable as ingredients in medical devices and even for the drug development route.
Dosages reported in published studies include:
- Fucoidan (anticoagulant clinical study): In a single-blind clinical study, 10 subjects received 3 g of fucoidan capsules for 12 days, with the control group receiving guar gum capsules.
- SXRG84 (Ulva-derived sulfated polysaccharide, metabolic RCTs): The first study used placebo, 2 g/day, or 4 g/day of SXRG84 daily for six weeks in 64 overweight or obese participants. The second study used placebo or 2 g/day of SXRG84 for six weeks in a crossover design with 64 participants.
- Fucoidan (diabetic rodent studies): Fuc-S treatment at 100 or 200 mg/kg for 5 weeks was used in STZ/HFD-induced diabetic mice.
- Chondroitin sulfate (osteoarthritis): CS has been used as a slow-acting drug for the treatment of osteoarthritis. Clinical dosing details vary by formulation; the key review finding was that pharmacologic-grade standardization influences efficacy.
Fucoidan is limited for use as a "complementary" ingredient in supplements, foods, beverages, cosmetics, and animal feed because its biological properties and safety have not been adequately demonstrated.
7. Safety Considerations and Interactions
7.1 Bleeding Risk
Propylene glycol alginate sodium sulfate (PSS), a sulfated polysaccharide derivative used as a heparinoid drug, carries bleeding risk that should not be overlooked. PSS fractions with low mannuronic acid/guluronic acid ratio and high molecular weight can excessively extend activated partial thromboplastin time (APTT) and thrombin time (TT), over-inhibiting thrombin activity mediated by anti-thrombin III to induce bleeding risk. The low M/G ratio fraction can also suppress platelet aggregation mediated by ADP and induce platelet reduction by improving platelet antibody in serum and by inhibiting or damaging the bone marrow hematopoietic function.
Heparin can cause adverse effects like bleeding and heparin-induced thrombocytopenia, complicating its use and prompting the search for safer anticoagulant alternatives.
7.2 Factor XII Activation and Hypotension
Sulfated galactans have no bleeding tendency, which is the major side effect of heparin and other antithrombotic drugs. Instead, the major side effect of these polysaccharides is activation of factor XII. This action results in the release of bradykinin, leading to severe hypotension. Pro-coagulant effect and hypotension, both due to activation of factor XII, instead of bleeding, may be the major obstacle for the therapeutic use of sulfated polysaccharides from marine organisms.
7.3 Contaminant Risk: Oversulfated Chondroitin Sulfate
Certain lots of heparin have been associated with an acute, rapid onset of significant side effects indicative of an allergic-type reaction. The Food and Drug Administration (FDA) identified "oversulfated chondroitin sulfate" as a contaminant in heparin originating from China. Chemically synthesized tetrasulfated disaccharide repeat units of chondroitin sulfate exhibit a high degree of anti-IIa activity, which could explain how contaminated heparin very easily passed activity screens, including whole blood coagulation tests.
7.4 Drug Interactions
There are several reports showing that taking chondroitin with glucosamine increases the effects of warfarin, which can cause bruising and bleeding that can be serious.
Sulfated polysaccharides exhibit favorable anticoagulant efficacy with reduced side effects compared to heparin in laboratory models; however, when taken with other anticoagulant medications, their additive effects on coagulation pathways may heighten bleeding risk, particularly given their structural and mechanistic similarities to heparin.
7.5 Carrageenan Safety Debate
The commonly used food additive carrageenan, including lambda (λ), kappa (κ) and iota (ι) forms, is composed of galactose disaccharides linked in alpha-1,3 and beta-1,4 glycosidic bonds with up to three sulfate groups per disaccharide residue. Carrageenan closely resembles the endogenous galactose or N-acetylgalactosamine-containing glycosaminoglycans (GAGs), chondroitin sulfate (CS), dermatan sulfate (DS), and keratan sulfate. Scientific debate persists regarding the safety of high-dose dietary carrageenan, particularly regarding its potential to promote intestinal inflammation in animal models at concentrations exceeding food additive levels.
7.6 Regulatory Status and Evidence Gaps
Fucoidan has not been approved as a human drug in any country, and no advanced clinical trials have been reported as of 2019. In 2004, a petition was submitted to the FDA that a dietary supplement of chondroitin sulfate be labeled as reducing the risk of osteoarthritis; the FDA denied the request, stating that experiments conducted by the company did not sufficiently demonstrate the effectiveness of the claim. Among other comments, the FDA noted the poor experimental design of some trials.
The link between the immunological mechanisms and structure of sulfated polysaccharides requires further exploration. Overall, the field of sulfated polysaccharide research is rapidly evolving, with a robust and growing preclinical evidence base but a relative paucity of well-powered, registered human clinical trials across most therapeutic indications.
References
Go back